Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04776018 · ClinicalTrials.gov registry record · Phase 1
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04776018 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 27 participants.
The verdict
NCT04776018, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM). The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combination with anti-CD38 (mAbs) and to determine the recommended Phase 2 dose (RP2D). Participants will be on this combination treatment for 28-day cycles. They will continue with this treatment until disease progression or unacceptable toxicity.
Interventions
- DRUG Daratumumab and Hyaluronidase-fihj
- DRUG Mezagitamab
- DRUG TAK-981
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2023-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04776018
The ClinicalTrials.gov registry entry for NCT04776018 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Daratumumab and Hyaluronidase-fihj is the first listed.
NCT04776018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04776018 about?
NCT04776018 is a clinical study titled "A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)". TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM). The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combination with anti-CD38 (mAbs) and to determine the r...
What is the current status of trial NCT04776018?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2021-04-20. Estimated completion is 2023-11-09.
What interventions are being tested in trial NCT04776018?
The interventions under investigation include: Daratumumab and Hyaluronidase-fihj (DRUG), Mezagitamab (DRUG), TAK-981 (DRUG).
Who is sponsoring clinical trial NCT04776018?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.